John D. Groopman spends much of his time researching Aflatoxin, Carcinogen, Hepatocellular carcinoma, Biochemistry and Pharmacology. His Aflatoxin study integrates concerns from other disciplines, such as Urine, Toxicology, Mycotoxin and Public health. His biological study spans a wide range of topics, including Virology, Carcinogenesis, Antigen, Molecular biology and Radioimmunoassay.
His biological study focuses on Liver cancer. His work on Affinity chromatography, DNA damage, Transfection and DNA is typically connected to Debrisoquine as part of general Biochemistry study, connecting several disciplines of science. John D. Groopman interconnects Erythromycin breath test, Oltipraz, In vivo and Sulforaphane in the investigation of issues within Pharmacology.
His primary scientific interests are in Aflatoxin, Carcinogen, Biochemistry, Hepatocellular carcinoma and Liver cancer. His Aflatoxin study combines topics from a wide range of disciplines, such as Cancer, Toxicology, Mycotoxin, Urine and Chromatography. In Carcinogen, John D. Groopman works on issues like Oltipraz, which are connected to Anticarcinogen.
His Biochemistry research focuses on subjects like Molecular biology, which are linked to In vivo and Mutation. His studies deal with areas such as Hepatitis B, Immunology, Virology and Pathology as well as Hepatocellular carcinoma. John D. Groopman has researched Liver cancer in several fields, including Epidemiology, Incidence, Environmental health, Vaccination and Cohort.
John D. Groopman mainly investigates Aflatoxin, Internal medicine, Hepatocellular carcinoma, Cohort and Liver cancer. His Aflatoxin research is multidisciplinary, incorporating perspectives in Cancer research, Environmental health, Carcinogen, Plasma samples and Mycotoxin. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Endocrinology and Oncology.
His work carried out in the field of Hepatocellular carcinoma brings together such families of science as Cancer, microRNA, DNA and Medical physics. Within one scientific family, John D. Groopman focuses on topics pertaining to Chromatography under DNA, and may sometimes address concerns connected to DNA damage. His research integrates issues of Mortality rate, Demography, Sex ratio, Etiology and Physiology in his study of Liver cancer.
The scientist’s investigation covers issues in Hepatocellular carcinoma, Aflatoxin, Cancer, Physiology and Cohort. In his study, which falls under the umbrella issue of Hepatocellular carcinoma, Chromatography, Adduct, Liquid chromatography–mass spectrometry, Guanine and Isotope dilution is strongly linked to DNA. His Aflatoxin study frequently links to related topics such as microRNA.
His work on Carcinogenesis as part of general Cancer research is frequently linked to Systemic therapy, bridging the gap between disciplines. As a member of one scientific family, John D. Groopman mostly works in the field of Environmental exposure, focusing on Hepatitis B and, on occasion, Liver cancer. His work focuses on many connections between Incidence and other disciplines, such as Gallstones, that overlap with his field of interest in Carcinogen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China.
Geng Sun Qian;Ronald K. Ross;Mimi C. Yu;Jian Min Yuan.
Cancer Epidemiology, Biomarkers & Prevention (1994)
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
Hirohide Yoshikawa;Kenichi Matsubara;Geng Sun Qian;Peta Jackson.
Nature Genetics (2001)
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
R. K. Ross;M. C. Yu;B. E. Henderson;J. M. Yuan.
The Lancet (1992)
The toxicology of aflatoxins: human health, veterinary and agricultural significance.
David L. Eaton;John D. Groopman.
Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology.
Thomas W. Kensler;Thomas W. Kensler;Bill D. Roebuck;Gerald N. Wogan;John D. Groopman.
Toxicological Sciences (2011)
Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries
Heather Strosnider;Eduardo Azziz-Baumgartner;Marianne Bänziger;Ramesh V. Bhat.
Environmental Health Perspectives (2006)
DNA damage by mycotoxins.
Jia Sheng Wang;John D. Groopman.
Mutation Research (1999)
Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.
Patricia A. Egner;Jin Bing Wang;Yuan Rong Zhu;Bao Chu Zhang.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Public Health Impacts of Foodborne Mycotoxins
Felicia Wu;John D. Groopman;James J. Pestka.
Annual Review of Food Science and Technology - (new in 2010) (2014)
Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens.
Alain Puisieux;Susan Lim;John Groopman;Mehmet Ozturk.
Cancer Research (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: